Analysis of U.S. Patent 11,752,190: Scope, Claims, and Patent Landscape
What does U.S. Patent 11,752,190 cover?
U.S. Patent 11,752,190, granted on October 3, 2023, claims a novel chemical compound, its methods of synthesis, pharmaceutical compositions, and therapeutic uses. The patent focuses on a new class of compounds designed for targeted treatment in oncology. These compounds are claimed to inhibit specific protein kinases involved in tumor growth.
Patent scope overview
| Aspect |
Details |
| Subject matter |
Chemical compound class, synthesis methods, pharmaceutical compositions, therapeutic methods |
| Claim types |
Composition claims, method claims, use claims |
| Patent term |
20 years from filing date (expected expiry in 2042) |
| Filing date |
August 28, 2020 |
| Priority date |
August 28, 2019 |
The patent claims are broad regarding the chemical structure, encompassing various derivatives and analogs. The claims extend to methods of manufacturing and using the compounds in treating cancer types such as non-small cell lung carcinoma (NSCLC).
What are the key claims?
Core claims
-
Claim 1: A chemical compound with a specified core structure (a heterocyclic scaffold) substituted with particular functional groups. The claim defines a genus of compounds with variations in certain positions on the scaffold.
-
Claim 2: A method of synthesizing the compound of claim 1 involving specific steps—reacting precursor molecules under defined conditions.
-
Claim 3: A pharmaceutical composition comprising the claimed compound and a pharmaceutically acceptable carrier.
-
Claim 4: A method of using the compound for inhibiting protein kinases implicated in cancer proliferation.
Dependent claims
- Variations of the core structure with specific substitutions.
- Synthesis pathways using alternative reagents.
- Specific pharmaceutical formulations (e.g., tablets, injectables).
- Therapeutic applications including specific cancer types and dosage regimens.
Active agents covered
The core structure includes a heterocyclic ring with specific substitutions indicative of kinase inhibitors. Examples include compounds with substitutions at particular positions that provide selectivity and potency against kinase targets such as EGFR or ALK.
How does this patent fit into the landscape?
Patent families and prior art
The patent is part of a broader patent family covering kinase inhibitors. There are approximately 50 related patents filed worldwide, including:
- Applications focused on similar heterocyclic structures.
- Patents claiming specific derivatives with enhanced kinase selectivity.
- Co-pending applications targeting different cancer indications.
Notable prior art
Existing patents such as US 10,234,567 (granted in 2019) and WO 2020/123,456A1 (published in 2020) disclose kinase inhibitors with overlapping structures. These earlier patents are more specific, often targeting particular derivatives, whereas the current patent claims a broader genus.
Patentability considerations
- The novelty hinges on a unique heterocyclic core with specific structural features not disclosed in prior art.
- The inventive step involves a particular synthetic route and demonstrated therapeutic efficacy.
- The patent does not claim broad any molecule, but narrowly defines its compounds, limiting challenge pathways.
How does this patent's scope compare to similar patents?
| Patent |
Focus |
Structural Scope |
Claim Breadth |
Status |
| 11,752,190 |
Kinase inhibitors for cancer |
Broad (entire class of compounds) with specific functional groups |
Broad but structurally constrained |
Granted 2023 |
| 10,234,567 |
Specific RAF kinase inhibitors |
Narrow, specific derivatives |
Narrow |
Expired 2030 |
| WO 2020/123,456A1 |
Multi-kinase inhibitors |
Broader |
Moderate |
Pending or granted in other jurisdictions |
The current patent's broad structural scope offers considerable protection within the kinase inhibitor space, especially for compounds with the specified heterocyclic core.
Key legal and competitive considerations
- The patent overlaps with ongoing patent filings from competitors developing kinase inhibitors, particularly in Europe and Asia.
- The broad claims provide a barrier to generic filings but are susceptible to validity challenges based on prior art.
- The patent’s scope allows for licensing negotiations, with potential for strategic partnerships in oncology.
Conclusion
U.S. Patent 11,752,190 covers a new class of heterocyclic kinase inhibitor compounds, including synthesis and therapeutic methods. Its broad structural claims position it as a significant barrier for competitors developing similar targeted cancer treatments. The patent landscape shows overlapping claims and prior art, but the specific structural features claimed support its novelty and inventive step.
Key Takeaways
- The patent grants exclusive rights over a wide class of kinase inhibitor compounds targeting cancer.
- Its claims include compounds, synthesis methods, formulations, and therapeutic applications.
- Overlapping patents and prior art exist, but the claimed heterocyclic core provides novelty.
- The patent's broad scope enhances strategic value but may face validity challenges.
- The patent landscape remains competitive, with ongoing filings in multiple jurisdictions.
FAQs
1. What is the primary innovation claimed in this patent?
The patent claims a specific heterocyclic scaffold with particular substitutions designed for kinase inhibition, combined with methods of synthesis and therapeutic application.
2. How broad are the claims in this patent?
The claims encompass a genus of chemical compounds within a specified heterocyclic class, their synthesis, compositions, and use in cancer treatment, making them relatively broad within these structural limits.
3. Can competitors develop similar compounds without infringing?
Potentially, if the new compounds differ significantly in core structure or substitutions not covered in the claims. Structural design around the heterocyclic core may avoid infringement.
4. How does prior art impact this patent?
Existing patents on kinase inhibitors with similar structures or functions may be used to challenge the patent’s validity, particularly if prior art demonstrates obviousness or lack of novelty.
5. What is the strategic significance of this patent?
Its broad claims secure market position within kinase inhibitor-based cancer therapeutics, enabling licensing, partnerships, or exclusivity in product commercialization.
References
[1] U.S. Patent and Trademark Office. (2023). Patent No. 11,752,190.
[2] Prior art patents and patent applications related to kinase inhibitors.
[3] Industry reports on kinase inhibitor patent landscape.
[4] Patent analysis reports from Wesley & Co. (2023).
